All | Type 1 diabetes | Type 2 diabetes | |
---|---|---|---|
(n=3,960) | (n=1,573) | (n=2,108) | |
Demographics | |||
Women | 54% (2,133/3,925) | 61% (958/1,572) | 48% (1,020/2,108) ‡ |
Age in years | 55 ± 14 | 47 ± 15 | 62 ± 10 ‡ |
Ethnic minority | 3% (104/3,884) | 2% (34/1,573) | 3% (58/2,108) |
Educational level | |||
Low | 27% (1,040/3,870) | 19% (293/1,571) | 33% (684/2,101) |
Middle | 34% (1,313/3,870) | 35% (546/1,571) | 34% (704/2,101) |
High | 39% (1,517/3,870) | 47% (732/1,571) | 34% (713/2,101) ‡ |
Having a partner | 80% (3,107/3,889) | 80% (1,260/1,573) | 80% (1,682/2,108) |
Paid employment | 48% (1,838/3,873) | 63% (992/1,571) | 36% (763/2,104) ‡ |
Clinical characteristics | |||
Duration of diabetes in years | 16 ± 13 | 23 ± 15 | 11 ± 8 ‡ |
Diabetes treatment | |||
Insulin pump | 24% (910/3,786) | 48% (761/1,572) | 6% (125/2,102) ‡ |
Insulin injections | 50% (1,891/3,786) | 53% (830/1,572) | 47% (995/2,102) † |
Glucagon-like peptide-1 (GLP-1) agonist injections | 2% (62/3,786) | 0.1% (2/1,572) | 3% (59/2,102) ‡ |
Blood glucose lowering tablets | 44% (1,627/3,664) | 7% (111/1,566) | 74% (1,474/1,987) ‡ |
Lifestyle only | 3% (99/3,726) | 0% (0/1,572) | 5% (95/2,042) ‡ |
Most recent HbA1c (mmol/mol) | 56 ± 12 | 58 ± 12 | 54 ± 12 ‡ |
Body Mass Index (kg/m2) | 28 ± 6 | 25 ± 5 | 30 ± 6 ‡ |
Macro-vascular disease and/or micro-vascular complications * | |||
None | 69% (2,544/3,691) | 70% (1,077/1,539) | 68% (1,383/2,041) |
One | 20% (729/3,691) | 18% (276/1,539) | 21% (436/2,041) |
Two or more | 11% (418/3,691) | 12% (186/1,539) | 11% (222/2,041) † |